Article Information
PubMed
Published By
History
- Received July 25, 2022
- Revision received December 12, 2022
- Accepted December 13, 2022
- Published online January 4, 2023.
Copyright & Usage
Copyright © 2023 Aghaizu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Author Information
- Nozie D. Aghaizu1,
- Sarah Jolly2,
- Satinder K. Samra1,
- Bernadett Kalmar3,
- Katleen Craessaerts5,6,
- Linda Greensmith3,
- Patricia C. Salinas4,
- Bart De Strooper1,5,6 and
- Paul J. Whiting1,2
- 1United Kingdom Dementia Research Institute at University College London, London WC1E 6BT, United Kingdom
- 2Alzheimer's Research UK Drug Discovery Institute (DDI), University College London, London WC1E 6BT, United Kingdom
- 3Department of Neuromuscular Diseases, University College London Queen Square Motor Neuron Disease Centre, Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom
- 4Department of Cell and Developmental Biology, University College London, London WC1E 6BT, United Kingdom
- 5Vlaams Instituut voor Biotechnologie Centre for Brain Disease Research, Leuven 3000, Belgium
- 6Department of Neurosciences and Leuven Brain Institute, Katholieke Universiteit Leuven, Leuven 3000, Belgium
- Correspondence should be addressed to Nozie D. Aghaizu at nozie.aghaizu{at}ucl.ac.uk or Sarah Jolly at sarah.jolly{at}ucl.ac.uk.
Author contributions
Author contributions: N.D.A., S.J., and P.J.W. designed research; N.D.A., S.K.S., B.K., K.C., L.G., P.C.S., B.D.S., and P.J.W. performed research; N.D.A. and S.J. contributed unpublished reagents/analytic tools; N.D.A. analyzed data; N.D.A., S.J., L.G., P.C.S., B.D.S., and P.J.W. wrote the paper.
Disclosures
The authors declare no competing financial interests.
This work was supported by the United Kingdom Dementia Research Institute, which receives its funding from DRI Ltd, funded by the United Kingdom Medical Research Council, Alzheimer’s Society, and Alzheimer’s Research United Kingdom. L.G. and B.K. are supported by Brain Research United Kingdom and the Rosetrees Trust.
Funding
DRI Ltd.
Brain Research UK (BRUK)
Rosetrees Trust (Rosetrees)
Other Version
- You are viewing the most recent version of this article.
- previous version (January 04, 2023).
Article usage
In this issue
Microglial Expression of the Wnt Signaling Modulator DKK2 Differs between Human Alzheimer’s Disease Brains and Mouse Neurodegeneration Models
